We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

84 hedge funds and large institutions have $624M invested in Adaptimmune Therapeutics in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 21

0.11% less ownership

Funds ownership: 12.74% → 12.62% (-0.11%)

2% less capital invested

Capital invested by funds: $637M → $624M (-$13.3M)

3% less funds holding

Funds holding: 87 → 84 (-3)

11% less call options, than puts

Call options by funds: $982K | Put options by funds: $1.11M

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

Holders
84
Holders Change
-3
Holders Change %
-3.45%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
28
Reduced
21
Closed
17
Calls
$982K
Puts
$1.11M
Net Calls
-$126K
Net Calls Change
-$589K

Top Buyers

Rank Fund Capital Flow
1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$6.35M
2
Rafferty Asset Management
Rafferty Asset Management
New York
+$5.06M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.76M
4
OAMG
Odey Asset Management Group
United Kingdom
+$3.15M
5
Citadel Advisors
Citadel Advisors
Florida
+$3.12M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$13.5M
2
Renaissance Technologies
Renaissance Technologies
New York
-$4.53M
3
Morgan Stanley
Morgan Stanley
New York
-$3.8M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$2.52M
5
PA
Perceptive Advisors
New York
-$2.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
26
ALPS Advisors
Colorado
$1.49M +$1.52K +265 +0.1%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$1.33M -$132K -23,093 -8%
SG Americas Securities
28
SG Americas Securities
New York
$1.25M +$1.34M +234,900 New
UBS Group
29
UBS Group
Switzerland
$998K +$37.2K +6,502 +4%
SFI
30
Susquehanna Fundamental Investments
Pennsylvania
$848K -$69K -12,060 -7%
QI
31
QS Investors
New York
$733K +$790K +138,000 New
Man Group
32
Man Group
United Kingdom
$718K +$182K +31,740 +31%
WM
33
WS Management
Florida
$614K -$34K -5,941 -5%
Renaissance Technologies
34
Renaissance Technologies
New York
$536K -$4.53M -791,095 -89%
Vontobel Holding
35
Vontobel Holding
Switzerland
$531K +$172K +30,000 +43%
GCP
36
GSA Capital Partners
United Kingdom
$494K -$1.31M -229,632 -71%
Citigroup
37
Citigroup
New York
$457K +$215K +37,498 +77%
HJIM
38
Henry James International Management
New York
$457K +$493K +86,070 New
Mitsubishi UFJ Asset Management
39
Mitsubishi UFJ Asset Management
Japan
$408K +$149K +26,013 +51%
VEA
40
Virtus ETF Advisers
New York
$389K +$7.34K +1,283 +2%
Geode Capital Management
41
Geode Capital Management
Massachusetts
$386K +$135K +23,581 +48%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$271K -$554K -96,757 -65%
AA
43
AlphaCentric Advisors
Puerto Rico
$271K +$40.1K +7,000 +16%
Goldman Sachs
44
Goldman Sachs
New York
$250K -$22.4K -3,910 -8%
TI
45
Trexquant Investment
Connecticut
$248K +$268K +46,742 New
DekaBank Deutsche Girozentrale
46
DekaBank Deutsche Girozentrale
Germany
$209K – – –
EGM
47
Engineers Gate Manager
New York
$208K +$224K +39,100 New
Squarepoint
48
Squarepoint
New York
$203K -$100K -17,487 -31%
VWM
49
Vigilare Wealth Management
Arizona
$199K +$114K +19,900 +114%
Simplex Trading
50
Simplex Trading
Illinois
$181K +$45K +7,868 +30%
1
2
3 4 5

ADAP Hedge Fund Activity: Q1 2021 in Review

84 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2021, worth a combined $624M — down 2.1% from $637M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of ADAP and 15 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 28 added.

The largest buyer was Baillie Gifford & Co, adding an estimated $6.35M. The largest seller was RA Capital Management, exiting entirely with an estimated $13.5M sold.

  • 84 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2021, down from 87 in Q4 2020.
  • Funds reported $624M of Adaptimmune Therapeutics stock for Q1 2021, down 2.1% quarter-over-quarter.
  • 15 funds opened new Adaptimmune Therapeutics positions in Q1 2021 and 17 closed out, a net change of -2 holders.
  • The largest Adaptimmune Therapeutics buyer in Q1 2021 was Baillie Gifford & Co, an estimated $6.35M added.
  • The largest Adaptimmune Therapeutics seller in Q1 2021 was RA Capital Management, an estimated $13.5M sold.

Based on aggregated 13F filings for Q1 2021.